Menu
Menu
Accurate and comprehensive genomic insights are increasingly essential for the diagnosis, classification, and risk stratification of myeloid malignancies — spanning single nucleotide variants, gene fusions, and large chromosomal aberrations. Yet consolidating these layers of genomic data into routine clinical workflows remains a significant bottleneck for many laboratories.
In this webinar, join Cecilia Lang, Biochemist and Head of Cytogenetics at Laboratorio de Especialidades Bioquímicas (LEB, Argentina), and Brandon Bullough, Product Marketing Director at SOPHiA GENETICS, as they explore how NGS-based molecular profiling with the SOPHiA DDM™ Myeloid Solution v2 (MYS2) can consolidate laboratory workflows and accelerate time-to-insights in the analysis of myeloid malignancies.
Brandon Bullough will open with an overview of SOPHiA DDM™ MYS2, tracing the need that drove its development and what sets it apart as a comprehensive myeloid solution. Cecilia Lang will then share her team's real-world experience implementing SOPHiA DDM™ MYS2 at a cytogenetics-focused reference center in Latin America — including its practical impact on day-to-day workflows and her perspective on where the field is headed.
Learning objectives
Speakers
Cecilia Lang
Head of Cytogenetics and FISH
Laboratorio de Especialidades Bioquimicas, LEB
Andrea Bender
Head of Molecular Biology
Laboratorio de Especialidades Bioquimicas, LEB
Brandon Bullough
Product Marketing Director, Blood Cancers
SOPHiA GENETICS
Real-world insights from Hospital Mário Penna
In this webinar, we explore how the MaxCare Program supported Hospital Mário Penna in implementing and adopting into routine two new NGS applications for the investigation of myeloid and lymphoid malignancies. The program empowered the local team to gain confidence in their results while assessing and establishing the analytical performance of the workflow.
Hospital Mário Penna shares their experience with SOPHiA GENETICS’ end-to-end implementation support, covering every step of the process—from strategic consultation and on-site training to data generation and analytical performance evaluation by the data science team, all tailored to the laboratory’s real-world context. The session concludes with the transition of these tests into routine practice, illustrated through two case studies: one in acute myeloid leukemia (AML) and the other in chronic lymphocytic leukemia (CLL).
Speakers:
Carolina Pereira de Souza Melo, PhD,
Researcher, Basic and Translational Oncology Research Laboratory, Instituto Mário Penna, Brazil
Gabrielle Martins Gonçalves, MSc,
SOPHiA GENETICS Implementation Scientist LATAM
Day: May 14th
Time: 11h BR/AR l 10h CL l 9h CO/PA l 8h MX/CR
Juan C. Gomez-Gelvez, MD
Section Head, Molecular Hematopathology — Henry Ford Health System
Measurable residual disease (MRD) represents the small number of leukemic cells that persist after treatment—undetectable by morphology yet clinically decisive. MRD status is now recognized as one of the strongest predictive and prognostic biomarkers in acute myeloid leukemia, influencing relapse risk, survival, and post-remission management.
In this on-demand session, Dr. Gomez-Gelvez walks through the principles, practicalities, and impact of using NGS to detect MRD with high sensitivity.
What You’ll Learn
Key Takeaways
Why Watch?
If you’re advancing AML diagnostics or shaping MRD strategies, this session provides clear, practical guidance from clinical concept through real-world application.
Melania Abreu González, MD/MS
Clinical Geneticist & Co-Founder, Genos Médica (Mexico)
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults across Western countries, but its incidence in Latin America is 3–5× lower, with some of the lowest rates observed in regions with high Amerindian ancestry. In Mexico, CLL represents only 7% of leukemia cases in Mestizo populations, making comprehensive molecular insights rare and highly valuable.
In this focused on-demand session, Dr. Abreu shares new learnings from targeted NGS analysis in the low-prevalence Mexican population and discusses how modern tools can reshape CLL assessment, stratification, and accelerate decision-making.
What You’ll Learn
Why Watch?
Get clear, real-world guidance on optimizing CLL workflows and generating meaningful insights in populations where data is limited.
Translating NGS Workflows into Real-World Impact in Hemato-Oncology
You are invited to join our networking event on hematologic malignancies during the 2025 Association of Molecular Pathologists Annual Meeting & Expo in Boston, USA.
Connect with peers and leading experts to explore how NGS-based solutions are advancing the investigation of complex variants in hematological malignancies.
During this event, speakers from renowned institutions will share real-world experiences implementing diverse NGS applications, including:
This is your opportunity to learn how peers are overcoming technical hurdles, realizing practical benefits, and applying NGS strategies to make genomic interpretation and decision-making in blood cancers more efficient.
What: Blood Cancer Showcase at AMP
Where: Omni Hotel - Marquee Room
Date: November 12th
Time: 6:30 pm – 8:15pm
Agenda to follow
Reserve your seat to this exclusive event on Wednesday, November 12th starting at 6:30 pm.
The diagnostic, prognostic, and treatment landscape of myeloid malignancies is evolving rapidly, with genomic biomarkers increasingly defining disease diagnosis and classification. Given the continuous discovery and refinement of genomic testing requirements in the context of changing (targeted) therapies and reimbursement recommendations, there is an increasing need for genomic solutions that keep pace with clinical and regulatory demands while remaining adaptive and flexible for future advancements.
In this webinar, Weei-Yuarn Huang, medical director for molecular diagnostics, and Hubert Tsui, head of hematological pathology, precision diagnostics and therapeutics program at the Sunnybrook Health Science Centre, will explore their recent experiences providing accurate, timely genomic results in myeloid malignancies and potential new solutions that will further enhance relevant biomarker delivery for hematology physicians and patients.
Measurable Residual Disease (MRD) is a crucial biomarker for analyzing and tracking tumor evolution, evaluating treatment effectiveness, and predicting relapse in acute myeloid leukemia (AML). Among the various technologies used to detect MRD, next-generation sequencing stands out for its exceptional sensitivity and specificity.
In this webinar, Silvia Salmoiraghi, biologist at ASST Papa Giovanni XXIII Hospital in Bergamo, Italy, discuss the performance of the SOPHiA DDM™ Residual Acute Myeloid (RAM) Solution.
We are thrilled to announce our participation in the ESMO Asia Congress 2024!
Join the SOPHiA GENETICS team at booth #E406 and explore how we are driving groundbreaking innovations in cancer research and treatment.
From our collaboration with Memorial Sloan Kettering cancer Center to decentralize MSK-ACCESS and MSK-IMPACT, to our launch of SOPHiA DDM™ Residual Acute Myeloid (RAM) Solution, we are committed to supporting clinical researchers with variant detection and analysis, biomarker discovery, and therapy selection.
We look forward to connecting with you at ESMO Asia 2024!
Lymphoid neoplasms encompassing lymphomas and some leukemia like Chronic Lymphocytic Leukaemia (CLL) are the most common type of blood cancer .
With increasing evidence for the stratification of tumor types with distinct clinical and biological features according to biomarkers, and the progress in targeted therapy, tailored NGS-based workflows empower experts to get high-quality and reproducible data to accelerate their studies. Watch our “SOPHiA DDM™ Community CLL Clonality Solution: The importance of biomarker analysis in CLL” webinar by Dr. Ferran Nadeu, Fundació de Recerca Clínic Barcelona-IDIBAPS, Molecular Pathology of Lymphoid Neoplasms Research Group.
Presented by: Dr. Ferran Nadeu, Fundació de Recerca Clínic Barcelona-IDIBAPS, Molecular Pathology of Lymphoid Neoplasms Research Group.
SOPHiA GENETICS™ is excited to be a part of the American Society of Hematology 2022 annual meeting, held in person in New Orleans, Louisiana from December 10-13.
You will have the chance to chat with our experts at booth #1915 and demo the universal SOPHiA DDM™ Platform.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.